HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and maintains a $19 price target.

May 07, 2024 | 6:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Travere Therapeutics with a $19 price target.
The reiteration of a Buy rating and maintenance of a $19 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Travere Therapeutics. This endorsement reaffirms the firm's confidence in the company's future performance and potential to reach the specified price target, likely leading to increased investor interest and potentially a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100